Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 11Brain Neoplasms 7Triple Negative Breast Neoplasms 5Stomach Neoplasms 3Neoplasms 3HER2-positive Breast Cancer 3Colorectal Neoplasms 3Advanced Breast Cancer 3Carcinoma, Non-Small-Cell Lung 2Breast Cancer With Brain Metastasis 2Unresectable Locally Recurrent Breast Cancer 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Meningeal Carcinomatosis 1Inflammatory Breast Neoplasms 1HER2-negative Breast Cancer 1HER2-low Hormone Receptor Positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1HER2 Overexpression 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × trastuzumab deruxtecan × Breast × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡